Market Signal Briefing

Journalist

Posted: November 18, 2025

Key Takeaways
Why are memecoins down?
The memecoin market has been down in the past week due to declining volume and increasing sell pressure.

Will memes gain ground again?
A shift in sentiment across the entire crypto sector could help memecoins regain their lost frenzy.

The memecoin market is down by about 1.4% in the last 24 hours, with the market cap dropping to $52.05 billion. The daily volume was also declining, commanding about $5.45 billion.

Memecoins led the hardest drops across crypto sectors alongside Layer 1s (L1s) and gaming, respectively. This raises the question of whether the memecoin frenzy is truly over for Q4 2025.

Weekly performance of top 10 memecoins
According to CoinMarketCap data, memecoins suffered the most in the past week, with the top 10 by capitalization experiencing double-digit losses.

All of them had dropped by figures between 9.9% and 30%, with SPX6900 [SPX] leading with losses. Shiba Inu [SHIB] lost the least amount of capital among this category.

After dropping more than 10%, Dogecoin [DOGE] was trading at $0.16. Other notable losers in the past seven days were Pepe [PEPE], Pudgy Penguins [PENGU], and Bonk [BONK], which all declined by more than 18%.

Source: CoinMarketCap

The performance of these top 10 memecoins reflected what was really happening for the broader sector.

This contradicts what took place in the last quarter of 2024 when AI memecoins debuted, for instance, Fartcoin [FARTCOIN].

But what was behind this shift in memecoin performance?

Why are memes down?
Memecoins were dropping harder than the entire crypto market, whose market cap reaches $3.25 trillion. Therefore, we can attribute the drop to the overall structure and sentiment of the crypto market.

Additionally, the memecoin volume was dropping very hard, suggesting traders were avoiding these markets. In fact, sell pressure was the dominant side even for those who were still trading the coins in this sector.

As per data from Stalkchain, sales volume exceeded the $1 million mark, while buyers accounted for half, slightly above $500K.

Source: Stalkchain

In this buying and selling contest, two memecoins stood out. The most bought token was FARTCOIN, which was more than 90% down from its ATH of $2.61. The smart money accumulated more than $350K worth of FARTCOIN.

On the other hand, Useless Coin (USELESS) was the most sold by the smart money in the past 24 hours. Similarly, its sell volume was close to $350K as per Stalkchain data, with price declining 21% on the day.

Final take: Is memecoin hype fading?
The market structure showed that memecoins have lost most of their capitalization and are leading the drop overall. They were the weakest in the entire crypto sector, which explained why their capital was fading that fast.

Altogether, the memecoin hype had faded, with capital now rotated to utility-based tokens like the DeFi sector, which was among the best gainers since the October 10th crash.

However, memecoins may regain their ground once sentiment is back.

Ethereum price failed to stay above $3,150 and extended losses. ETH is down over 5% and might struggle to recover above $3,200 in the near term.

Ethereum started a fresh decline after it failed to stay above $3,150.
The price is trading below $3,100 and the 100-hourly Simple Moving Average.
There is a key bearish trend line forming with resistance at $3,150 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move down if it settles below the $3,000 zone.

Ethereum Price Turns Red
Ethereum price failed to continue higher above $3,150 and started a fresh decline, like Bitcoin. ETH price dipped below $3,180 and entered a bearish zone.

The decline gathered pace below $3,120 and the price dipped below $3,000. A low was formed at $2,955 and the price is now correcting some losses. There was a move toward the 23.6% Fib retracement level of the recent decline from the $3,562 swing high to the $2,955 low.

Ethereum price is now trading below $3,150 and the 100-hourly Simple Moving Average. If there is another recovery wave, the price could face resistance near the $3,050 level. The next key resistance is near the $3,150 level. There is also a key bearish trend line forming with resistance at $3,150 on the hourly chart of ETH/USD.

Source: ETHUSD on TradingView.com
The first major resistance is near the $3,260 level and the 50% Fib retracement level of the recent decline from the $3,562 swing high to the $2,955 low. A clear move above the $3,260 resistance might send the price toward the $3,350 resistance. An upside break above the $3,350 region might call for more gains in the coming days. In the stated case, Ether could rise toward the $3,450 resistance zone or even $3,500 in the near term.

More Downside In ETH?
If Ethereum fails to clear the $3,150 resistance, it could start a fresh decline. Initial support on the downside is near the $2,950 level. The first major support sits near the $2,880 zone.

A clear move below the $2,880 support might push the price toward the $2,750 support. Any more losses might send the price toward the $2,680 region in the near term. The next key support sits at $2,650 and $2,640.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is gaining momentum in the bearish zone.

Hourly RSI – The RSI for ETH/USD is now below the 50 zone.

Major Support Level – $2,950

Major Resistance Level – $3,150

Bitcoin fell to nearly $90,000 on November 17.

getty

Bitcoin prices took a tumble on Monday, November 17, extending their recent losses and reaching their lowest point in over six months.

The world’s most prominent digital currency fell to $90,128.00 during the day, according to Coinbase data from TradingView.

At this point, the cryptocurrency was trading at its most depressed level since approximately April 21, additional Coinbase figures provided by TradingView reveal.

When explaining the latest price declines, analysts pointed to several factors, but generally painted a picture of deteriorating market conditions.

“Bitcoin’s decline is coming from a mix of profit-taking, shrinking liquidity, and macro pressures,” DiPasquale, CEO of cryptocurrency hedge fund manager BitBull Capital, stated via email.

“Long-term holders have been selling into strength after the run-up to all-time highs, and that’s put meaningful supply back into the market,” he continued.

“Liquidity has also deteriorated, so the market simply can’t absorb large sell orders the way it did earlier in the year,” the market observer added.

“At the same time, tighter financial conditions and rising concerns about credit risk have pushed investors out of higher-beta assets, and crypto is feeling that rotation immediately.”

“The combination of weaker liquidity, derisking by institutions, and long-term holders taking profit has accelerated the move lower,” said DiPasquale.

MORE FOR YOU

Maja Vujinovic, CEO and cofounder of Digital Assets at FG Nexus, also commented on the weakening conditions in the cryptocurrency markets.

“Bitcoin’s slide is driven by a convergence of macro and market structure factors,” she stated through email. “We’ve moved into a clear risk-off environment, tech, growth, and high-beta assets all sold off as investors priced in higher-for-longer interest rates.”

“In turn, that shift pulled capital out of the Bitcoin ETFs, where hedge funds and fast-money allocators were taking profits after a massive run-up,” the analyst continued.

Julio Moreno, head of research for CryptoQuant, also weighed in, speaking to falling demand.

“I think this is a follow up price correction happening in the context of broad bearish conditions in crypto markets,” he said via Telegram when asked what was driving bitcoin’s most recent declines.

“Specifically, the demand for Bitcoin and crypto assets from US investors have been contracting, as seen by negative flows of ETFS and a negative Bitcoin Coinbase price premium,” Moreno added.

Credit RisksOne analyst took a broader view, emphasizing bitcoin’s recent correlation to risk assets and voicing concerns about the credit markets.

“Bitcoin and Crypto in general have become very correlated to ‘risk-assets’ as of late,” Greg Magadini, director of derivatives for digital asset data provider Amberdata claimed via email.

“Today the market is beginning to reflect nervousness around credit. Almost all western governments are running large spending deficits on top of already large debt burdens while the stock market is being led higher by AI related stocks,” he added, pointing out what he views as potential risks.

“Something like 40% of the S&P-500 has exposure to AI in some form,” Magadini continued. “This becomes a problem if the AI driven growth needs to be financed through large credit issuances to finance future CapEx, ahead of meaningful organic revenue.”

The derivatives expert was not alone in highlighting AI as a potential threat to assets like stocks and cryptocurrencies, as David Brickell, head of international distribution for FRNT, stated via Telegram that “Broader risk assets are also under pressure amid concern over an AI-driven tech bubble."

Brickell also offered an outlook on liquidity, stating that “With the government shutdown resolved, liquidity should gradually return as the Treasury General Account is spent down, but ahead of major U.S. data releases, markets remain cautious and defensive.”

Bitcoin Crashes Under $90K as Death Cross Creates 'Extreme Fear' SentimentThe drop to $89,420 — its lowest level since February — comes just six weeks after prices topped out at a record $126,250, marking a sharp reversal.Updated Nov 18, 2025, 3:44 a.m. Published Nov 18, 2025, 3:44 a.m.

Bitcoin plunged below $90,000 on Monday in Asian hours, extending a selloff that has now erased the entirety of its 2025 gains and pushed sentiment into one of its most depressed readings of the cycle.
The drop to $89,420 — its lowest level since February — comes just six weeks after prices topped out at a record $126,250, marking a sharp reversal.

The slide accelerated after Bitcoin failed to reclaim key support at $93,700 over the weekend, breaking below its 200-day moving average and triggering a “death cross” between the 50-day and 200-day trendlines.

STORY CONTINUES BELOW

That signal, while imperfect, tends to coincide with multi-week drawdowns when accompanied by evaporating liquidity and stalled ETF inflows — both of which are now visible.

Flows into the U.S. spot ETFs, which absorbed more than $25 billion earlier in the year, have flatlined for nearly two weeks amid concerns that the Trump administration’s tariff agenda could inject another round of inflation and delay Federal Reserve rate cuts.

Corporate balance-sheet buyers that aggressively accumulated in the first half of the year have likewise paused purchases.

Retail stress is deepening. The crypto Fear & Greed Index fell to 11 on Monday, its lowest print since the 2022 bear market, signaling “extreme fear.”

Social dominance for Bitcoin — the share of marketwide chatter tied to BTC — has spiked, a pattern that historically appears near local capitulation events as traders abandon altcoins to focus on the benchmark asset.

Analysts warn that failure to reclaim $93,000 in the near term leaves a clear liquidity pocket toward $86,000–$88,000.

Still, some note that sentiment shocks of this magnitude often precede short-term relief rallies if ETF outflows stabilize and macro data turns less hawkish in the coming weeks.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

Asia Morning Briefing: Even Prediction Markets Didn’t See Bitcoin’s Selloff Coming

3 hours ago

A fast reset in downside odds mirrors QCP’s warning of flat-footed pro desks, with Glassnode highlighting oversold momentum and moderating ETF outflows.

What to know:

Bitcoin's recent slide has led to a significant sentiment shift in prediction markets, with traders now viewing the decline as a deeper structural issue.On-chain data suggests bitcoin is experiencing late-stage capitulation pressures, though some analysts argue the market lacks the final ingredient for a true bottom.Bitcoin and Ether have both seen declines, with Bitcoin down 27% from last month's high and Ether extending its weekly decline to 15%.Read full story

It’s been hard to overlook Walmart’s (WMT - Free Report)  steady growth, while Target’s (TGT - Free Report)  cheaper valuation may still compel investors as a potential buy-the-dip target.

To that point, ahead of their Q3 results this week, Walmart stock is up a very respectable +14% in 2025, with Target shares down a grizzly 30%.

Seeing as past performance is not always indicative of future success, this certainly makes it a worthy topic of which retail stock may be the better investment as their Q3 reports approach.  

Target & Walmart’s Q3 ExpectationsSet to report on Wednesday, November 19, Target’s Q3 sales are thought to have dipped 1% to $25.36 billion. On the bottom line, Target’s Q3 EPS is expected to be down 5% to $1.76. Notably, Target has missed the Zacks EPS Consensus in three of its last four quarterly reports with an average EPS surprise of -8.44%.

Image Source: Zacks Investment Research

As for Walmart, which reports on Thursday, November 20, Q3 sales are expected to be up over 4% to $177.14 billion. Even better, Walmart’s Q3 EPS is slated to rise 5% year over year to $0.61. Walmart has exceeded earnings expectations in three of its last four quarterly reports, with an average surprise of 2.79% despite most recently missing Q2 EPS estimates by nearly 7%.  

Image Source: Zacks Investment Research

Walmart’s Success & Target’s WoesSummarizing their contrasting stock performances, Walmart has used e-commerce to leverage its massive global scale and grocery dominance while expanding into higher-margin businesses such as advertising, memberships, marketplace services, and vertical integration in food supply chains.  

In the last five years, WMT has stellar gains of over +100% with Walmart now bringing in more than $100 billion in digital sales annually.

Meanwhile, TGT is down over 45% during this period as Target has struggled with weaker sales growth, narrower margins, and less resilience to consumer spending shifts after previously being somewhat of a Wall Street darling as it relates to retail stocks.

Image Source: Zacks Investment Research

TGT & WMT Valuation ComparisonSurely attracting investor interest is that Target stock is trading at a steep discount to the benchmark S&P 500's 25X forward earnings multiple and the broader Zacks Retail and Wholesale sectors' 27X. It’s also noteworthy that TGT is trading at a 20% discount to its decade-long median of 15X forward earnings.

Walmart, on the other hand, trades at 39X forward earnings, although its EPS growth has been justifiable of a premium.

In terms of price to forward sales, TGT and WMT both trade at the often preferred level of less than 2X.

Image Source: Zacks Investment Research

Dividend Comparison & Final ThoughtsAs dividend kings that have increased their payouts for at least 50 consecutive years, Walmart and Target are both making the argument for being viable long-term investments at their current levels.

That said, their Q3 reports will be critical to gauging if Walmart stock still has more upside or if Target’s is due for a rebound, with WMT and TGT both landing a Zacks Rank #3 (Hold) at the moment.  

Of course, Walmart’s steady expansion may make it a better long-term choice in terms of stock appreciation. Although a sharper turnaround in Target’s operational efficiency has been much needed, its reliable 5.07% annual dividend yield could still be more attractive regarding total return potential going forward compared to Walmart’s 0.92%.

LifeMD, Inc. (LFMD) Q3 2025 Earnings Call November 17, 2025 4:30 PM EST

Company Participants

Justin Schreiber - Chairman & CEO
Marc Benathen - Chief Financial Officer

Conference Call Participants

David Larsen - BTIG, LLC, Research Division
Steven Valiquette - Mizuho Securities USA LLC, Research Division
Anderson Schock - B. Riley Securities, Inc., Research Division
Sarah James - Cantor Fitzgerald & Co., Research Division
Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Good afternoon. Thank you for joining us today to discuss LifeMD's results for the third quarter ended September 30, 2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session.

Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings, and within other filings that LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, November 17, 2025. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law.

Also, please note that management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today.

Finally, I would like to remind everyone that today's call is being recorded and will be available for

Recommended For You

By

PYMNTS
 | 
November 17, 2025

 | 

Equifax said Monday (Nov. 17) that it acquired Vault Verify, a company that offers services that include employment and income verification.

This acquisition enhances the data that Equifax already provides to verifiers and provides another mechanism for employers to provide data to a verifications provider, Equifax said in a Monday press release.

Vault Verify provided a link to the release on the home page of its own website.

The acquisition of Vault Verify provides additional information to Equifax’s The Work Number database, including information that can help consumers when they apply for jobs, mortgages, social service benefits and other financial services, according to the release.

“Leveraging the power of our Equifax Cloud transformation, we are able to rapidly integrate Vault Verify into ongoing Equifax operations and deliver verifiers the information they need quickly and efficiently,” Equifax CEO Mark Begor said in the release.

Vault Verify, an Equifax company, is now part of the Equifax Workforce Solutions business unit, and members of the Vault Verify team have assumed roles within that business unit, per the release.

Advertisement: Scroll to Continue

Joe Muchnick, chief operating officer at Equifax Workforce Solutions, said in the release: “We are excited about the enhanced set of knowledge and capabilities that our combined Vault Verify and Equifax teams will be able to offer as we seek to help streamline life’s important moments through secure, efficient verifications.”

Equifax said in an October earnings report that its revenue was up 7% year over year in the third quarter, despite what it called headwinds from the U.S. hiring and mortgage markets.

During the company’s previous earnings call, held in July, Begor said that the Workforce group had seen hiring transactions slow due to economic uncertainty but had seen its government business remain positive as “states implement stronger verification requirements aligned with these new government requirements.”

In October, Equifax launched a generative artificial intelligence (AI) solution that helps lenders analyze portfolio performance, identify growth opportunities and improve decision-making through conversational data insights.

This Equifax Ignite AI Advisor solution is built on the Equifax Cloud, powered by its Amplify AI engine, and merges lenders’ internal data with Equifax’s proprietary credit and risk analytics.

TOKYO--(BUSINESS WIRE)--Mitsui Chemicals invites applications for the 2026 Catalysis Science Award until Dec 25, 2025, across diverse catalysis and materials science fields.

Sezzle has been a big winner over its history. The recent pullback could be an opportunity.

We're nearing the end of 2025, and it looks set to be another winning year for the stock market, continuing the artificial-intelligence-driven bull market that began with the launch of ChatGPT.

However, more recently, stocks are showing signs of weakness as murmurs about an AI bubble are growing louder.

One of the most vulnerable sectors has been fintech, as a number of fintech stocks have fallen sharply in recent weeks on concerns about a weakening credit environment, declining consumer confidence, and a labor market that has soured.

One stock that has tumbled sharply in recent weeks is Sezzle (SEZL 2.24%), the buy now, pay later (BNPL) specialist that has delivered exceptional growth in recent quarters. As you can see from the chart below, however, Sezzle has fallen 43% since Sept. 9, the day before Klarna's IPO, underperforming other declining fintech peers.

Is the sell-off in Sezzle an opportunity? Here's what you need to know about the hot BNPL stock.

Image source: Getty Images.

Sezzle is still sizzling
Sezzle stock skyrocketed on soaring growth earlier this year, but the stock plunged in August on its second-quarter earnings report. While the company beat analyst estimates, management did not raise its full-year guidance, indicating an expected moderation in its growth rate in the second half of the year.

Sezzle stock fell again on Nov. 6 on its third-quarter earnings report as it easily beat analyst estimates and raised its EPS guidance for the year. However, CFO Karen Hartje, who built the company's finance team, said she intended to resign for personal reasons, leaving a significant gap in the company's leadership. Hartje will serve as CFO while the company searches for her replacement.

Despite the market's reaction to Sezzle's results, its numbers have been strong. In the third quarter, gross merchandise volume -- the total spend on the platform -- jumped 58.7% to $1 billion, and revenue jumped 67% to $116.8 million as the company's monthly on-demand users and subscribers, which it calls MODS, rose 36,000 in the quarter to 784,000.

On the bottom line, its performance was also strong, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rising 75% to $39.6 million, and adjusted earnings per share from $0.47 to $0.71.

Sezzle was a late entrant in the BNPL arena and has had to be scrappy to gain market share. Its business model is similar to that of other BNPL operators. It offers a "pay in four" feature and makes most of its money from merchants, who pay a 6% processing fee plus $0.30 on transactions.

The company also presents itself as more user-friendly and less predatory than its peers. For example, it cuts off users if they miss payments, which limits its own credit risk and gives users an incentive to pay their bills.

Its subscription products have been popular and include Sezzle Anywhere, which allows users to use Sezzle virtually anywhere Visa is accepted.

Today's Change

(

-2.24

%) $

-1.17

Current Price

$

50.97

Could Sezzle 10x?
While Sezzle is under pressure like other fintech stocks, this could be an attractive buying opportunity. Based on its updated adjusted EPS of $3.38 for the year, the stock now trades at a forward P/E of just 16, which is incredibly cheap for a company growing this fast.

That seems to reflect investor skepticism about the growth potential of the business as well as its rising credit risk in the current macro environment. However, while credit risk may be going up, the pressure on the consumer also creates more opportunity for Sezzle, as it's likely to drive more people to use its product. In the third quarter, its provision for credit losses doubled to $32.2 million, a potential warning sign.

However, if Sezzle can get through the current volatile market environment unscathed, the stock could move a lot higher from here, considering its valuation, its growth rate, and the large market opportunity in BNPL. Given its current market cap of $1.8 billion, a 10x gain isn't out of the question if Sezzle can maintain a strong growth rate.

November 17, 2025 9:08 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"), of the important December 29, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Avantor common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Avantor class action, go to https://rosenlegal.com/submit-form/?case_id=47303 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) Avantor's competitive positioning was weaker than defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, defendants' representations about Avantor's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Avantor class action, go to https://rosenlegal.com/submit-form/?case_id=47303 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274943

Pfizer's weight management pipeline just got a boost.

Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade, handsomely rewarding any drugmaker that establishes itself as a leader in the field.

Right now, that's none other than Eli Lilly (LLY 0.20%). However, others are looking to challenge its dominance. Recent comments from Pfizer's (PFE +0.08%) CEO, Albert Bourla, suggest it could become one of the companies that successfully carve out a niche in the weight management space. Let's see what Bourla said, and what it means for investors.

Image source: Getty Images.

This acquisition catapulted Pfizer near the front of the line
On Nov. 13, Pfizer finalized its acquisition of Metsera, a smaller drugmaker with several weight loss candidates in the pipeline. The deal cost Pfizer $7 billion in cash and could be worth up to $10 billion once milestone payments kick in. There are at least two important clues that tell us Metsera has its hands on some exciting candidates.

The first is that Pfizer had to battle an established leader in the field, Novo Nordisk, to complete this acquisition. After the former company put in a bid, the latter stepped in with a higher one. Pfizer eventually won the race. But the fact that two pharmaceutical giants, including one with a proven history of developing breakthrough medicines in this area, wanted Metsera under their wings is worth mentioning.

Today's Change

(

0.08

%) $

0.02

Current Price

$

25.08

Second, Metsera's actual clinical trial results look promising. In a phase 2 study, Metsera's leading candidate, MET-097i, demonstrated substantial weight loss and highly encouraging tolerability. It might be one of the more promising mid-stage assets, especially once we set aside those being developed by Eli Lilly and Novo Nordisk.

Pfizer's CEO certainly thinks so. In a TV interview, Bourla said: "Pfizer, when it plays, plays big. And we will -- as we did in COVID, as we did with Lipitor, as we did with ... Viagra, as we did with all the medicines that we have invented and brought to the market -- we will do the same with obesity."

Lipitor, a medicine used to manage blood cholesterol levels, was the best-selling drug in history at one point, though it has since been supplanted. Pfizer's COVID products peaked at near $57 billion in revenue in 2022 and helped it become the first biopharma company to generate $100 billion in annual sales. Comparing its weight management efforts to those successes speaks volumes about where Bourla thinks Pfizer will land in this field.

But is it enough to dethrone Eli Lilly?
Pfizer expects to launch its first anti-obesity drug by the end of 2028. In the meantime, though, Eli Lilly has a considerable lead. The latter company already has Zepbound on the market, a medicine whose sales have been growing exceptionally well. Meanwhile, Lilly could launch a few more products in this field by 2028.

First, there's orforglipron, an oral GLP-1 medicine that posted strong phase 3 results in both diabetes and obesity this year. Orforglipron could earn approval by early next year, given that Eli Lilly has received a new voucher from the U.S. Food and Drug Administration that allows for expedited review.

Today's Change

(

-0.20

%) $

-2.07

Current Price

$

1023.21

Then, there's Eli Lilly's retatrutide, a medicine currently in phase 3 studies. Retatrutide mimics the action of three gut hormones -- GLP-1, GIP, and glucagon -- and this approach could lead to increased efficacy. The therapy performed very well in mid-stage studies and could post phase 3 results relatively soon.

Next month, Eli Lilly plans to start a phase 3 study for another candidate, eloralintide, which recently completed phase 2 studies. In short, Lilly's existing lineup and pipeline in anti-obesity looks strong enough to fend off the competition. Though others will eventually join the market and generate strong sales from their weight loss medicines, Eli Lilly seems likely to remain the leader for the foreseeable future.

Is Pfizer stock a buy?
Pfizer's financial results have been disappointing over the past few years. And one of its top growth drivers, Eliquis, an anticoagulant, is facing a patent cliff within a few years, so at first glance, the drugmaker's outlook does not look bright. But with a deep pipeline, Pfizer seems likely to turn things around.

Metsera's assets will take center stage now, given the rapid growth of the weight-loss market. If Pfizer can achieve the kind of success in this area that Bourla is predicting, the company should rebound. But it has other exciting candidates, especially in oncology. My view is that Pfizer will succeed in its turnaround, thanks to its pipeline and to a lineup of newer products that should eventually contribute to its top line.

That's to say nothing of the company's strong dividend program, which should appeal to investors. With all that in mind, Pfizer's shares look attractive at current levels.

These companies continue to prove their worth.

If you're looking for stocks capable of performing well over long periods, it's a good idea to start with companies that are well-established leaders in industries with excellent long-term prospects. These include sectors such as e-commerce, cloud computing, and fintech. Here are two corporations, each a top player in two of those industries: Amazon (AMZN 0.74%) and MercadoLibre (MELI +0.45%). These market leaders have crushed broader equities over the long run, but they might still just be getting started. Here's what investors need to know.

Image source: Getty Images.

1. Amazon
In the U.S., Amazon has a leading share of the e-commerce market. The company also leads the global cloud computing industry. Part of the tech giant's success is that it identified these opportunities faster than almost every other corporation and benefits from a first-mover advantage. However, that's only part of the story. Amazon also developed a robust competitive advantage from multiple sources, allowing it to maintain its leading position. In e-commerce, the company built deep network effects and a strong brand name. And within its cloud division, Amazon Web Services (AWS), it benefits from high switching costs.

Today's Change

(

-0.74

%) $

-1.74

Current Price

$

232.95

The company has several catalysts that could help it improve its results over the long run. The first is that both industries still have pretty low penetration. For instance, e-commerce sales made up only 16.3% of total retail sales in the U.S. as of the second quarter. It almost certainly hasn't peaked. In the cloud, CEO Andy Jassy has noted that 85% of IT spending still occurs on-premises, despite the advantages of cloud computing.

Also, Amazon should improve efficiency, partly thanks to AI. Its e-commerce division has low margins, but the company is working to improve profitability. Amazon unleashed a fleet of robots whose travel efficiency in its warehouses will be improved thanks to AI. The goal is to reduce the company's costs while speeding up customer delivery times. And Amazon's cloud division is also benefiting from increased demand for AI-related services.

The company does have several other growth avenues. Amazon's advertising business has been growing as fast -- sometimes even faster -- than its cloud division, for instance.

Meanwhile, the company's financial results remain strong: Third-quarter revenue and earnings grew at a good clip. Overall, Amazon's excellent results, economic moat, and strong growth prospects make it likely to outperform the market over the long run. That's why the stock is a buy today.

2. MercadoLibre
MercadoLibre is the leading e-commerce platform in South America. That's why it is sometimes dubbed "The Amazon of Latin America." However, MercadoLibre's business is different from that of its U.S.-based competitor. Yes, it is the largest e-commerce platform in the region, but it also has a massive fintech arm, Mercado Pago, and a service that helps merchants build customized online storefronts, called Mercado Shops. One reason MercadoLibre has performed well is that it's been hard for competitors to replicate its reach across Latin America.

The company's presence spans multiple regions, some of which are challenging to navigate due to political instability. But MercadoLibre has successfully done so, building strong network effects and switching costs in the process. That almost guarantees it will remain a leader for the foreseeable future, even if we put aside the significant upfront investments companies would need to build the sort of infrastructure MercadoLibre already has in the region.

Today's Change

(

0.45

%) $

9.18

Current Price

$

2058.07

Even with more challengers, MercadoLibre should benefit in the long run as the e-commerce and fintech markets expand significantly. Latin America has been one of the fastest-growing e-commerce markets in the world in recent years, and the industry should continue to grow at a good clip. MercadoLibre has already benefited from its efforts. Revenue has grown at a good pace for a long time, and the company has been consistently profitable for a few years now. Thankfully, it's not too late to buy the stock given its long-term outlook.

The SPDR S&P Biotech ETF is a compelling investment option.

Biotech investing can feel a little bit like a Vegas sportsbook sometimes. Pick the company with the right drug trial and you could be swimming in profits. Miss that pick and you could easily see your investment getting cut in half.

Investing, of course, isn't gambling. And there are conditions that investors looking to make good decisions should be aware of when assessing the health of the biotech space. Such as the ones that are developing right now.

A pair of macro tailwinds are building that could drive biotech returns heading into 2026. The sector has been outperforming the S&P 500 since August, and the trend could still be in the early innings.

Let's look at what's driving the biotech sector right now and why the SPDR S&P Biotech ETF (XBI +0.72%) could be a great way to play the sector.

Regulation and the return of dealmaking
If there's one downside to the biotech sector, it's time. From discovery to approval, new drugs can take 10 years before they finally hit the market. Along the way, companies may spend millions of dollars pushing a treatment through the process, all in the hope of generating revenue from it at some point years down the road. It's estimated that fewer than 10% of the drugs that enter the clinical trial stage ultimately get approved for commercial use.

It's a big reason why biotech investing can be a "feast or famine" proposition and why it comes with a high degree of risk.

But a blunting of risk might be on the way. 

President Donald Trump has made deregulation a focus of his second administration. So far, it has mostly focused on the financial and cryptocurrency sectors, including efforts to reduce oversight from the Consumer Financial Protection Bureau (CFPB) and promote more widespread acceptance of cryptocurrencies.

Some think those efforts could soon extend to the healthcare space, which is one of the economy's more heavily regulated sectors. While it's still unclear what this could look like, how long it might take to implement, or if anything Trump puts in place would extend beyond his term, fewer regulations would have the potential to lower compliance costs and speed up the drug approval process. 

But that's only part of the story.

Image source: Getty Images.

The other potential catalyst is mergers & acquisitions (M&A). An increase in M&A activity is generally a sign of insider optimism about where the sector is heading. Executives tend to pursue acquisitions when they believe that the economy or their sector will keep expanding, financing is relatively inexpensive, or growth opportunities exist that could justify the price.

According to Leerink Partners, the number of biotech deals already announced in 2025 exceeds the average annual deal count of the past 15 years. The pharma sector saw a 71% increase in venture financing deals -- which involve investors giving money to early-stage companies -- in Q3 2025 compared to the previous quarter. The total was around $3 billion. 

It's clear that a larger pattern is developing here. Companies are seeing a positive outlook for the biotech sector and are increasing the amount of money being invested in it. Deregulation could be fuel on the fire for that pace of activity.

The biotech sector is finally beginning to wake, and one ETF may be well-positioned to capture these emerging trends.

Why XBI is built for this kind of setup
There are several exchange-traded funds (ETFs) that give you exposure to the biotech space, but I think the simplest approach is probably the best.

The SPDR S&P Biotech ETF tracks the S&P Biotechnology Select Industry Index, which seeks to provide equal weighted, unconcentrated industry exposure across large-, mid- and small-cap stocks.

Today's Change

(

0.72

%) $

0.82

Current Price

$

114.83

The key feature here is the lack of concentration. Instead of being an ETF that maintains overweight positions in heavyweights such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals, XBI equal-weights across more than 100 different companies. That means SPDR S&P Biotech ETF investors are getting better exposure to the industry's themes and innovations instead of relying on the success of just a few big companies.

Also consider that the majority of new drug developments and innovations over the past decade came from smaller biotech companies. It makes a lot of sense to include those companies in your portfolio as opposed to just focusing on the big ones. Risks get spread out, and you get exposure to a wider set of opportunities.

The SPDR S&P Biotech ETF has an expense ratio of 0.35%, which is typical for ETFs focused on biotech or medical advancements. It's up 25% year-to-date as of Nov. 14, and has delivered a 10.5% average annual return since its 2006 inception.

In short:

Equal weighting reduces company-specific risk.
Large companies buying small companies, where the majority of drug development is happening, can result in big acquisition premiums.
Diversification reduces the reliance on trying to pick individual winners. Instead, it focuses on the sector's success.

The case for biotech keeps getting better
Investing in biotech will probably always require taking on some risk, but the current setup might be the best it's been in years.

Policy momentum is shifting toward deregulation. Dealmaking, a sign of industry and investor confidence, is accelerating. Money is flowing back into the sector. We're already seeing stock prices start to reflect these catalysts, and the upside may not be over. The SPDR S&P Biotech ETF is probably one of the cleanest ways to invest in biotech.

The story may just be getting started.

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Baxter class action, go to https://rosenlegal.com/submit-form/?case_id=17664 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants misled investors by failing to disclose that: (1) the Novum IQ Large Volume Pump (“Novum LVP”) suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) based on the foregoing, Baxter’s statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Baxter class action go to https://rosenlegal.com/submit-form/?case_id=17664 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

SAN FRANCISCO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- On November 5, 2025, investors in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw the price of their shares tumble $15.63 (-15%) after the company announced its Q3 2025 financial results and revealed cancelation of emerging markets distributor orders, prompting one analyst to question management’s guidance philosophy.

The developments and significant market reaction have prompted shareholder rights law firm Hagens Berman to open an investigation into whether Zimmer Biomet may have violated the federal securities laws.

The firm urges investors who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Visit: www.hbsslaw.com/investor-fraud/zbh
Contact the Firm Now: [email protected]
                                               844-916-0895

Zimmer Biomet Holdings (ZBH) Investigation:

The investigation is focused on the propriety of Zimmer Biomet’s statements about the reasonableness of management’s assumptions going into its forecasting process.

As recently as Zimmer Biomet’s August 7, 2025 Q2 2025 earnings call, the company’s management assured investors that its updated 2025 year-over-year organic revenue growth forecast of 3.5% to 4.5% would be achieved in large part because of “the emerging markets distributor purchase[]” and said “I’ll be very surprised if Q3 is not a number scratching 6%.”

Management also assured investors that “I have more conviction in our strategy and team than ever” and “our confidence in the second half revenue growth expectation is very high.”

These statements drove the price of the company shares up over 7% that day.

Investor disappointment set in on November 5, 2025. That day, Zimmer Biomet reported its results for Q3 2025 revealing that year-over-year organic revenue growth was just 5%. The company also reduced its top-line organic revenue growth forecast to 4% and revealed that “emerging markets represented a headwind to growth.”

In addition, Zimmer Biomet revealed that during the quarter it experienced distributor orders cancelations in emerging markets, mainly the Middle East and Eastern Europe, it widely missed its forecast in Latin America, and it is “making leadership and governance changes in some of our international businesses to address some of the headwinds that we’ve seen in these geographies throughout the year 2025.”

In response to an analyst’s question during the earnings call about management’s guidance philosophy, the company’s CEO (Ivan Tornos) assured the analyst that “effective today” “we, or rather I need to be far more measured in our external commentary.”

The market swiftly reacted, sending the price of Zimmer Biomet shares down 15% that day.

“We’re investigating the extent to which company leadership was aware of the apparently quite serious headwinds in its emerging markets business and, if so, whether it accurately informed investors by last August,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Zimmer Biomet and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Zimmer Biomet investigation, read more »

Whistleblowers: Persons with non-public information regarding Zimmer Biomet should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

, /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.

So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the MoonLake Immunotherapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or mailto:call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

The digital currency XRP has experienced a notable decline, with its price dropping to $2.15 from its recent high. This downturn has resulted in about 30-35% of XRP's total supply being held at a loss, marking the lowest profitability for its holders since the early months of 2024.

On November 17, 2025, the public sale of Monad's native token on Coinbase launched with an impressive start, amassing approximately $43 million in just 30 minutes. Market watchers had anticipated strong initial interest due to Monad's reputation and its promise to enhance blockchain efficiency through innovative technology.

Cover image via www.freepik.com

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The market's structure is far from being bullish, but we might finally enter a proper, predictable downtrend, as assets like XRP show a clear price tendency. Meanwhile, Bitcoin risks losing six digits, while Dogecoin shows unimpressive performance from bears. 

Bitcoin's major riskFollowing a severe decline that eliminated weeks of bullish positioning Bitcoin is currently trading at about $95,500. The price is now below all of the major moving averages including the 50-day 100-day and 200-day and the most recent attempt at a bounce has already stalled indicating a clear structural shift on the chart. 

The clock is running out for any realistic chance to reach six-digit territory and the market is at a point where the next directional move will probably determine the remainder of the cycle. The drawdown itself is not the issue the context is. The $100,000 psychological level which was supposed to act as a new baseline earlier this year is now firmly below Bitcoin. It became resistant instead. 

HOT Stories

BTC/USDT Chart by TradingViewThis is no longer a transient decline, because the 50-day and 200-day averages are declining. It's a change in trend and if bulls don't quickly recover important levels the next stage might involve a protracted grind below $100,000. 

The RSI is currently close to 34 indicating strong sell pressure but not total capitulation. As a result Bitcoin may decline. Red candle volume has also increased suggesting forced selling rather than accumulation. The last time this occurred it took weeks for Bitcoin to stabilize and this situation appears to be comparable if not worse. 

Bitcoin needs to close above the 200-day moving average and break back above $105,000 in order to have any chance of reaching six figures during this cycle.

The six-digit narrative would then require strength to return to $112,000-$115,000. However investors should get ready for a situation where triple digits become the exception rather than the rule if Bitcoin is unable to swiftly recover $100,000 particularly with weekly closes trending downward. 

In 2026, the market would probably move into a macro lower high eventually aiming for the $80,000-$85,000 range before potentially drifting toward the 200-week moving average.

XRP settles downAt last, XRP’s price structure has settled into a clear descending channel which is no longer unclear. Following weeks of erratic movements and false starts, the chart now displays a distinct pattern that helps traders understand what's going on and where it might go next.

Since early October, the price has been making lower highs and lower lows, and the descending channel is now clearly visible. Because it offers structure rather than chaos, this is important.

You Might Also Like

The bias remains bearish as long as XRP stays within this channel, and any bounce within this trend should be treated with suspicion until it is demonstrated otherwise. The problem is highlighted by the moving averages.

The 50-day, 100-day, and 200-day MAs are all below XRP’s current price, indicating a decline. There isn’t a healthy uptrend for any asset in that posture.

Downside risk is still present because the RSI, around 44, indicates that there is still space to drop before reaching full capitulation levels. The good news is that violent reversals frequently occur at the end of descending channels.

A distinct shift would be indicated if the price breaks above the upper channel line with volume, or if the lower boundary is tested and holds. In that case, XRP might recover $2.70 and begin to move back toward the mid-$3s.

Dogecoin bears are weakDogecoin has been declining for weeks, but the volume, or rather the absence of it, is the most telling aspect of this trend rather than the price. The fact that DOGE is drifting lower on decreasing volume indicates that this is not a selloff motivated by panic. It is apathy.

In terms of price, DOGE has remained below all significant moving averages. The asset is being compressed, and a clear bearish structure is confirmed because the 50-day, 100-day, and 200-day MAs are all above the current price levels.

You Might Also Like

There isn’t much momentum, and even the most recent candles don’t indicate that buyers are desperate to make up lost ground. RSI is bearish but not oversold at about 40.

However, this decline differs from a brutal capitulation due to its volume. Neither sell pressure nor fear-driven exits have sharply increased. DOGE is not collapsing, rather it is relaxing.

Additionally, historically low-volume downtrends frequently indicate one of two things: either the market is quietly losing interest just before a reversal, or there is a gradual bleed toward a collapse. The latter is a plausible scenario in the case of Dogecoin.

It is evident from the low volume that sellers are not actively dumping. Additionally, it indicates that whales are not further depressing the market. This is not like the loud, frantic blow-offs that are typical of DOGE’s major price tops. 

DOGE is currently trading close to the $0.17-$0.16 range. It might start building the foundation for its next move if it can maintain this region and prevent a breakdown toward $0.14. Volume must return for that to occur, but it must be a steady, controlled inflow from traders positioning ahead of a change in the tone of the market rather than a huge explosion driven by memes.

A new survey suggests that the ongoing ideological clash within the Bitcoin developer community is receiving almost no attention from institutional investors. While the debate between supporters of Bitcoin Core and Bitcoin Knots has grown increasingly heated online, large financial players appear unmoved and largely uninterested.

Ethereum has launched Kohaku, its most ambitious privacy push yet.

Institutional SOL transfers highlight evolving treasury strategies and shifting portfolio management practices within the Solana ecosystem.

Key Takeaways

Forward Industries transferred approximately $260 million worth of Solana (SOL) tokens to Coinbase Prime.
The transfer signals a significant movement of SOL to an institutional custody and trading platform.

Forward Industries, the largest Solana treasury entity backed by Galaxy Digital, Multicoin, and Jump Crypto, moved around $260 million worth of Solana tokens to Coinbase Prime today, according to Arkham Intelligence data.

The transfer represents a significant movement of SOL tokens to an institutional custody platform. Coinbase Prime provides trading and custody services specifically designed for institutional clients.

Forward Industries recently reported that its SOL stash reached 6.9 million SOL as of Nov. 15. The firm highlighted gains in SOL per share driven by capital deployment, institutional-grade validator operations, and enhanced staking.

Large SOL transfers by treasury firms like Forward Industries to institutional platforms have drawn attention as potential portfolio realignments within the Solana ecosystem. Such movements are monitored as possible stake adjustments or internal treasury maneuvers.

Disclaimer

Bitcoin is entering one of the most decisive weeks of the year as it trades near $93,000, its lowest level in six months. After a 7% decline last week, the asset has now logged three consecutive weekly losses.

The Dogecoin multi-year recovery trend is under pressure as price slips below a key ascending support and rests on an historic horizontal level, according to a new chart from trader and analyst Rekt Capital.

Dogecoin Is Inches Away From A Bear Market
In an X post, Rekt Capital shared a 1-month DOGE/USDT chart from Binance, created on TradingView on Nov. 15, and warned: “Dogecoin needs to protect its multi-year technical uptrend heading into December to keep chances for macro upside alive.”

The chart tracks Dogecoin from the 2021 blow-off top through the 2022–2023 bear market and the subsequent recovery. A rising trendline, built from the bear-market lows, currently runs just below the $0.18 region and has defined what Rekt Capital calls DOGE’s “multi-year technical uptrend.”

Dogecoin price analysis, monthly chart | Source: X @rektcapital
The latest monthly candle, however, shows Dogecoin trading around $0.16355, beneath that trendline and pressed against a horizontal support level near $0.159. That horizontal area is not arbitrary. On the monthly timeframe it has repeatedly flipped role between resistance and support over the last two years.

From May to October 2024, the ~$0.159–0.16 band acted as a ceiling, repeatedly rejecting upside attempts. The eventual breakout above this level in October 2024 preceded an explosive move: Dogecoin’s price nearly tripled from roughly $0.16 to a December high of $0.4843.

In 2025, the same zone then became crucial support. Between March and July, monthly candles showed downside wicks piercing below intramonth, but closes repeatedly held above the level, confirming it as a major structural floor.

What To Watch Now
That history is what makes the current retest so significant. With roughly half the month remaining, the red November candle has already lost the rising trendline near $0.18 and is now depending on the long-standing $0.159–0.16 horizontal area to arrest further downside. On a monthly chart, what matters is not just the intramonth excursion but where the candle closes.

If DOGE can reclaim and close back above the trendline, the pattern of higher lows that has defined the multi-year uptrend would remain largely intact. A monthly close decisively below the horizontal level, by contrast, would mean both the ascending support and this historically pivotal price floor have failed, materially weakening the macro bullish structure.

For now, Dogecoin sits exactly on that line in the sand. As Rekt Capital put it, DOGE “needs to protect its multi-year technical uptrend heading into December” if it is to avoid sliding back toward a bear-market profile.

At press time, DOGE traded at $0.1626.

DOGE holds above the 200-week EMA for now, 1-week chart | Source: DOGEUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com